help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

  Click here to read this article as a CME course


First Published Online April 2, 2009
The Oncologist, Vol. 14, No. 4, 425-432, April 2009; doi:10.1634/theoncologist.2009-0002
© 2009 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
theoncologist.2009-0002v1
14/4/425    most recent
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mendler, J. H.
Right arrow Articles by Friedberg, J. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mendler, J. H.
Right arrow Articles by Friedberg, J. W.

Lymphoma

Salvage Therapy in Hodgkin's Lymphoma

Jason H. Mendler, Jonathan W. Friedberg

James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, New York, USA

Key Words. Hodgkin • Lymphoma • Relapse • Refractory • Salvage • Transplant

Correspondence: Jonathan W. Friedberg, M.D., University of Rochester Medical Center, 601 Elmwood Avenue, Box 704, Rochester, New York 14642, USA Telephone: 585-273-4150; Fax: 585-276-0337; e-mail: Jonathan_Friedberg{at}urmc.rochester.edu

Received January 1, 2009; accepted for publication February 13, 2009; first published online in THE ONCOLOGIST Express on April 2, 2009.

Disclosures

Jason H. Mendler: None; Jonathan W. Friedberg: Honoraria: Lilly; Research funding: Cephalon, Millennium.

Section editor George P. Canellos has disclosed no financial relationships relevant to the content of this article.

The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias.

Hodgkin's lymphoma (HL) is a commonly cured malignancy. Unfortunately, patients who are refractory to or relapse after first-line treatment pose a significant therapeutic challenge. There is evidence that these patients are best treated with an approach involving salvage chemotherapy followed by high-dose chemotherapy and autologous stem cell transplant (HDCT/ASCT). This approach may result in cure, with better results in patients with low-risk relapse. In patients with high-risk relapse and refractory disease, HDCT/ASCT is rarely curative. More aggressive transplant approaches have shown promising results in this group and are currently under active investigation. For those relapsing after HDCT/ASCT, there exists a range of therapeutic options, including further salvage chemotherapy, reduced-intensity allogeneic transplantation, monoclonal antibody therapy, and novel agents. All patients in this category should be considered for enrollment in clinical trials. This review discusses the evidence behind the current practice in patients with relapsed or refractory HL. Specifically, the efficacy of various salvage chemotherapy regimens, the risk factors influencing outcome with HDCT/ASCT, and the results with alternative transplant approaches, monoclonal antibody therapies, and novel agents are addressed. We conclude by providing our approach to these patients, with the hope that this will serve as a framework for the practicing oncologist.







HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2009 by AlphaMed Press.